Reuters logo
4 months ago
BRIEF-Sanofi receives FDA approval of Thymoglobulin for prevention of acute kidney transplant rejection
April 24, 2017 / 12:49 PM / 4 months ago

BRIEF-Sanofi receives FDA approval of Thymoglobulin for prevention of acute kidney transplant rejection

April 24 (Reuters) - Sanofi SA:

* Sanofi receives FDA approval of Thymoglobulin® for the prevention of acute kidney transplant rejection

* Sanofi- FDA approved thymoglobulin for use in conjunction with concomitant immunosuppression in prophylaxis of acute rejection in patients receiving kidney transplant Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below